dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Piha-Paul, Sarina |
dc.contributor.author | Geva, Ravit |
dc.contributor.author | Tan, Tira |
dc.contributor.author | Lim, Darren Wan-Teck |
dc.contributor.author | Hierro Carbó, Cinta |
dc.contributor.author | Doi, Toshikiko |
dc.date.accessioned | 2022-06-07T12:56:38Z |
dc.date.available | 2022-06-07T12:56:38Z |
dc.date.issued | 2021-08 |
dc.identifier.citation | Piha-Paul SA, Geva R, Tan TJ, Lim DW, Hierro C, Doi T, et al. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. J Immunother Cancer. 2021 Aug;9(8):e002863. |
dc.identifier.issn | 2051-1426 |
dc.identifier.uri | https://hdl.handle.net/11351/7635 |
dc.description | Anticossos; Combinació; Neoplàsia |
dc.description.sponsorship | This study was supported by Novartis Oncology. |
dc.language.iso | eng |
dc.publisher | BMJ |
dc.relation.ispartofseries | Journal for ImmunoTherapy of Cancer;9(8) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Lymphoma |
dc.title | First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1136/jitc-2021-002863 |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | neoplasias |
dc.subject.decs | linfoma |
dc.relation.publishversion | http://dx.doi.org/10.1136/jitc-2021-002863 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Piha-Paul SA] Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [Geva R] Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. [Tan TJ] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada. [Lim DW] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. [Hierro C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Molecular Therapeutics Research Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Doi T] Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan |
dc.identifier.pmid | 34389618 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |